Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
Authors
Keywords
-
Journal
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2021-07-09
DOI
10.1111/bcp.14980
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial
- (2020) Raphael J Landovitz et al. Lancet HIV
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study
- (2020) Edgar T Overton et al. LANCET
- HIV Viral Load and Transmissibility of HIV Infection
- (2019) Robert W. Eisinger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Changes in HIV Preexposure Prophylaxis Awareness and Use Among Men Who Have Sex with Men — 20 Urban Areas, 2014 and 2017
- (2019) Teresa Finlayson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial
- (2018) Raphael J. Landovitz et al. PLOS MEDICINE
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
- (2017) Martin Markowitz et al. Lancet HIV
- Defining success with HIV pre-exposure prophylaxis
- (2015) Jessica E. Haberer et al. AIDS
- On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
- (2015) Jean-Michel Molina et al. NEW ENGLAND JOURNAL OF MEDICINE
- The long-acting integrase inhibitor GSK744 protects macaques from repeated intravaginal SHIV challenge
- (2015) J. Radzio et al. Science Translational Medicine
- A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge
- (2015) Chasity D. Andrews et al. Science Translational Medicine
- GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
- (2014) William Spreen et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-Acting Integrase Inhibitor Protects Macaques from Intrarectal Simian/Human Immunodeficiency Virus
- (2014) C. D. Andrews et al. SCIENCE
- Clinical Pharmacology Quality Assurance for HIV and Related Infectious Diseases Research
- (2013) R DiFrancesco et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
- (2013) W. Spreen et al. HIV CLINICAL TRIALS
- Preexposure Prophylaxis for HIV Prevention
- (2013) Jared M. Baeten et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Long-acting injectable antiretrovirals for HIV treatment and prevention
- (2013) William R. Spreen et al. Current Opinion in HIV and AIDS
- Preexposure Prophylaxis for HIV Infection among African Women
- (2012) Lut Van Damme et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More